Adults Over 65: Evidence-Based Longevity Strategies for Hormones, Brain Health, and Physical Performance

Why the Physiology of Adults Over 65 Demands a Different Protocol Than Midlife

Aging past 65 is not simply a continuation of what happens at 50. By the mid-sixties, most adults have accumulated compound physiological changes: gonadal hormone output has declined substantially, anabolic signaling through IGF-1 and mTORC1 is blunted, mitochondrial density in skeletal muscle has dropped measurably, and the brain's metabolic glucose utilization begins shifting in ways that raise Alzheimer's risk. These changes interact with each other, which means a single-intervention approach almost always falls short.

The HEALTH ABC cohort (N=3,075 adults aged 70-79) tracked over six years and found that low muscle mass at baseline predicted 2.3 times higher risk of mobility disability independent of body fat [1]. Separately, data from the Baltimore Longitudinal Study of Aging showed that testosterone levels in men dropped an average of 110 ng/dL per decade after age 50, a rate faster than earlier estimates [2].

Adults over 65 who are still athletic or who maintain high physical activity often assume their lab values will stay in healthy ranges. That assumption is frequently wrong. Even competitive masters athletes commonly show hypogonadism, low bone mineral density, and early signs of anabolic resistance by their late sixties, particularly in endurance sports where chronic cortisol elevation accelerates gonadotropin suppression.

Family history of dementia introduces a separate urgency. Adults with one first-degree relative with Alzheimer's disease have approximately 10-30% lifetime risk compared with roughly 10% in the general population, and APOE4 homozygotes face a 3-4x elevation in that risk [3]. For this subgroup, interventions targeting brain metabolism and neuroinflammation, including hormone optimization and metabolic control, carry a higher expected benefit-to-risk ratio.

Hormone Therapy Over 65: What Current Evidence Actually Supports

The clinical picture for hormone therapy in adults past 65 is more favorable than the post-2002 WHI panic suggested. The WHI Memory Study, which frightened many clinicians away from postmenopausal estrogen, enrolled women with an average age of 71 who started conjugated equine estrogen 15+ years after menopause. That is a fundamentally different scenario from initiating therapy near menopause or continuing therapy that was started earlier.

The "critical window" or "timing hypothesis" is now supported by multiple analyses. The Cache County Study (N=1,357 women) found that women who used hormone therapy within five years of menopause had a 30% lower incidence of Alzheimer's disease compared with never-users, while those starting more than 10 years after menopause showed no benefit and possibly a slight increase in risk [4]. The Menopause Society's 2023 position statement states directly: "For women aged younger than 60 years or within 10 years of menopause onset, the benefit-risk ratio is favorable for treatment of bothersome menopause symptoms and for prevention of bone loss or fracture" [5].

For women over 65 who are already on MHT and have no contraindications, the evidence does not support automatic cessation at an arbitrary birthday. A 2023 NEJM Evidence review by Manson and colleagues concluded that continuing well-tolerated MHT beyond age 65 in low-risk women may preserve bone density and quality of life without a clear increase in cardiovascular events when transdermal estradiol is used rather than oral conjugated estrogens [6].

In men, testosterone replacement therapy (TRT) for documented hypogonadism has a clearer evidence base in this age group. The TRAVERSE trial (N=5,246 men aged 45-80 with hypogonadism and elevated cardiovascular risk) published in NEJM in 2023 found that testosterone therapy did not increase the incidence of major adverse cardiovascular events (MACE) compared with placebo over a mean 33-month follow-up, with a hazard ratio of 0.96 (95% CI 0.78-1.17) [7]. This was a landmark finding that should change how clinicians counsel older hypogonadal men about cardiovascular risk.

Doses typically used in men over 65 are often conservatively targeted to the lower half of the normal range, roughly 400-550 ng/dL total testosterone, to minimize hematocrit elevation, which was observed at a higher rate in the TRAVERSE trial (19.2% testosterone group vs. 12.3% placebo, P<0.001).

GLP-1 Receptor Agonists in Older Adults: Preserving Metabolic Function Without Sacrificing Muscle

GLP-1 receptor agonists including semaglutide and tirzepatide are now widely discussed for adults over 65, but the conversation often ignores the single most important concern in this population: body-composition changes during weight loss.

STEP-1 (N=1,961 to 68 weeks) showed 14.9% mean body weight loss with semaglutide 2.4 mg versus 2.4% with placebo [8]. The sub-analysis of older participants (age 65+) from STEP-5 (N=304 to 104 weeks) confirmed sustained weight loss of approximately 15.2% at 68 weeks. However, DXA substudies consistently show that 25-40% of total mass lost during GLP-1 therapy is lean mass rather than fat, a ratio that becomes clinically significant when baseline muscle mass is already borderline.

The practical implication for adults over 65 is that GLP-1 therapy should almost never be used without a simultaneous high-protein diet (minimum 1.2 g per kg body weight per day) and a structured resistance training program. The ESPEN expert consensus statement on nutrition in older adults explicitly sets 1.2-1.6 g per kg per day as the target for those undergoing active weight loss [9].

Tirzepatide (GIP/GLP-1 dual agonist) may hold a slight advantage in lean mass preservation compared with semaglutide alone, based on early SURMOUNT-1 sub-analyses, though head-to-head data in adults over 65 specifically remains limited. Clinicians prescribing either agent in this age group should track handgrip strength and gait speed at each visit, not just body weight on a scale.

Sarcopenia and Resistance Training: The One Intervention With Essentially No Downside

Sarcopenia, defined by the European Working Group on Sarcopenia in Older People 2 (EWGSOP2) as low muscle strength plus low muscle quantity or quality, affects an estimated 10-40% of community-dwelling adults over 65 depending on diagnostic cutoffs used [10]. Left untreated, it doubles the risk of falls and increases all-cause mortality risk substantially.

Resistance training is the only intervention with consistent Grade A evidence for both prevention and partial reversal of sarcopenia in this age group. A meta-analysis of 49 randomized controlled trials published in the British Journal of Sports Medicine (N=1,079 adults aged 65-80) found that progressive resistance training produced a weighted mean increase in leg press strength of 34% and a 1.1 kg gain in lean mass over 20 weeks [11].

Adults over 65 respond well to resistance training even without hormonal optimization, though the combination of TRT plus resistance training in hypogonadal men produces roughly twice the lean mass gains of either intervention alone, based on data from the Testosterone Trials (TTrials) sub-studies [12].

Athletes over 65 need a modified periodization strategy. Recovery time between sessions is genuinely longer than in younger decades, and connective tissue remodeling is slower, so two to three sessions per week with 48-72 hours between sessions is better-tolerated than daily training. Blood flow restriction (BFR) training at 30-40% of one-repetition maximum has emerged as a valuable option for older athletes managing joint pain or injury history, producing hypertrophy signals similar to higher-load training with substantially less mechanical stress.

Cognitive Decline and Dementia Prevention: Practical Protocols for High-Risk Adults

Adults with a family history of dementia or known APOE4 status face a higher-stakes calculus for every lifestyle and pharmacological decision. The good news is that modifiable risk factors account for roughly 40% of dementia cases globally, according to the 2024 Lancet Commission on Dementia Prevention update [13].

The 12 modifiable risk factors identified by the Lancet Commission include: untreated hearing loss, hypertension, obesity, alcohol use, head injury, physical inactivity, smoking, depression, social isolation, air pollution, diabetes, and low education. Addressing all 12 could theoretically prevent or delay 40% of dementia cases. For adults over 65 with a positive family history, the Lancet Commission specifically recommends blood pressure control to below 130/80 mmHg as the single highest-yield modifiable target, given the strong evidence linking midlife and late-life hypertension to dementia risk.

Estrogen's role in neuronal metabolism is particularly relevant here. The brain contains abundant estrogen receptors, particularly in the hippocampus and prefrontal cortex, and estradiol promotes mitochondrial function and reduces amyloid-beta accumulation in animal models. The WHIMS sub-study found harm with CEE alone in older women (mean age 71), but that harm was likely a function of timing, oral delivery, and progestin type, rather than estrogen itself. Transdermal estradiol combined with micronized progesterone (rather than medroxyprogesterone acetate) is associated with a more neutral or favorable cerebrovascular risk profile based on observational data from the E3N cohort (N=80,377 French women) [14].

For APOE4 carriers specifically, emerging data from the SPRINT MIND trial (N=9,361) found that intensive systolic blood pressure control targeting below 120 mmHg reduced probable dementia by 17% and mild cognitive impairment by 19% compared with standard treatment targeting below 140 mmHg [15]. That is a significant and actionable finding for any adult over 65 with a family history of dementia.

Omega-3 fatty acids, specifically DHA at 1,000-2 to 000 mg per day, show modest but consistent associations with slower cognitive decline in observational data, though the ASCEND-Mind trial did not find a statistically significant benefit in a general older adult population. The APOE4-specific subgroup analyses are ongoing and may show differential benefit.

Bone Health Over 65: Beyond "Take Calcium and Come Back in Five Years"

Fracture risk in adults over 65 is frequently underestimated and undertreated. The FRAX tool, endorsed by the International Osteoporosis Foundation, estimates 10-year fracture probability based on clinical risk factors and DXA T-scores. Adults over 65 with a T-score below -2.5 at the femoral neck meet WHO criteria for osteoporosis and qualify for pharmacological treatment.

First-line therapy for most older adults remains bisphosphonates. Alendronate 70 mg weekly has demonstrated a 47% reduction in hip fracture risk in the Fracture Intervention Trial (FIT, N=2,027 postmenopausal women with low bone density) [16]. For men over 65, zoledronic acid 5 mg annually has shown a 25% reduction in morphometric vertebral fractures in the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly (HORIZON-PFT) trial [17].

Hormone therapy's role in bone preservation over 65 is direct and well-documented. The WHI bone sub-study found that women randomized to CEE plus medroxyprogesterone acetate had a 33% lower risk of hip fracture compared with placebo, the strongest non-bisphosphonate data for bone protection in postmenopausal women [18]. This benefit carries over to transdermal estradiol formulations, which generally show equivalent or superior bone-protective effects with a more favorable clotting risk profile.

Testosterone therapy in hypogonadal men over 65 raises bone mineral density at the lumbar spine and femoral neck, with the TTrials bone sub-study showing a 7.5% increase in volumetric BMD at the lumbar spine after 12 months of treatment [19].

Cardiovascular Risk Management Specific to Adults Over 65

Cardiovascular disease remains the leading cause of death for adults over 65 in the United States. The ACC/AHA 2019 Primary Prevention Guideline recommends recalculating 10-year ASCVD risk using the Pooled Cohort Equations every 4-6 years, with coronary artery calcium (CAC) scoring used as a tie-breaker for intermediate-risk patients [20].

For older adults specifically, a CAC score of zero in a 65-74-year-old suggests lower cardiovascular event rates and may justify withholding statin therapy or aspirin in otherwise borderline patients. A CAC score above 100 or above the 75th percentile for age-sex-race category essentially reclassifies that person to high risk regardless of Pooled Cohort Equation results.

Statin therapy in adults over 65 without prior cardiovascular events remains a nuanced decision. The ASPREE trial (N=19,114, median age 74) found that aspirin 100 mg daily in healthy older adults did not reduce cardiovascular events but significantly increased major hemorrhage, including intracranial bleeding [21]. This landmark finding effectively ended routine primary-prevention aspirin use in adults over 65, though statin evidence in this group remains more favorable.

GLP-1 receptor agonists carry an additional cardiovascular benefit that becomes relevant for older adults with type 2 diabetes or established cardiovascular disease. The LEADER trial (liraglutide, N=9,340) and SUSTAIN-6 trial (semaglutide 0.5/1.0 mg, N=3,297) both demonstrated significant reductions in MACE in high-cardiovascular-risk populations, with effects seen across age groups including adults over 65 [22].

Nutritional Biochemistry for Adults Over 65: Targeting the Specific Deficits

Standard adult dietary reference intakes do not adequately reflect the biology of adults past 65. Three specific nutrients deserve heightened attention: vitamin D, vitamin B12, and protein distribution throughout the day.

Vitamin D deficiency is present in roughly 41% of U.S. adults and is even more common in adults over 65 due to reduced sun exposure, decreased dermal synthesis efficiency, and impaired renal conversion of 25-OH-D to active 1,25-OH-D. Serum 25-OH-D levels below 20 ng/mL are associated with increased fracture risk, fall risk, and all-cause mortality. Supplementation at 1,500-2 to 000 IU per day typically achieves target levels of 40-60 ng/mL in most adults, though some individuals require 3,000-4 to 000 IU to normalize levels [23].

Vitamin B12 absorption declines with age because of reduced gastric acid production and decreased intrinsic factor secretion. Adults over 65 with atrophic gastritis or on proton pump inhibitors are particularly vulnerable. Serum B12 below 300 pg/mL can contribute to peripheral neuropathy, macrocytic anemia, and cognitive impairment that is sometimes misattributed to early dementia. Oral supplementation at 1 to 000 mcg per day, or sublingual/intramuscular forms for those with severe malabsorption, generally restores levels adequately.

Protein timing matters as much as total intake. The anabolic response to a single protein bolus is blunted in older skeletal muscle, a phenomenon called anabolic resistance. To overcome this, older adults need roughly 30-40 g of high-quality protein per meal to achieve the same muscle protein synthesis stimulus that a younger adult would get from 20-25 g. Three meals each containing 30-40 g of leucine-rich protein (whey, eggs, lean meat, or soy) distribute the anabolic signal more effectively than a low-protein breakfast and a high-protein dinner.